MedTrace Logo

Prevention of Radiodermatitis in Breast and Head and Neck Cancer Patients in Cyprus

NCT05588973 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-12-06

No results posted yet for this study

Summary

The treatment of cancer as a multidimensional disease has improved in recent years with the development of new chemotherapies, targeted biological therapies or radiation therapy protocols and have led to an overall improvement in the survival of oncology patients. These treatments often cause adverse effects on the skin, which can be accompanied by physical and mental suffering and have a significant impact on patients' quality of life. Improving the quality of life of patients is today a therapeutic challenge. The objective of this clinical study is to assess the tolerability of an innovative skin cosmetic product that will be developed specifically for use during curative anticancer treatments, as well as to study the impact on quality of life of skin side effects caused by the treatments.

Conditions

Interventions

OTHER

MEDISKIN cream

MEDISKIN cream with collagen

OTHER

Panthenol cream

Panthenol cream

Sponsors & Collaborators

  • German Oncology Center, Cyprus

    collaborator OTHER

  • RSL Revolutionary Labs Ltd

    collaborator UNKNOWN

  • Angelos Kassianos

    lead OTHER

Principal Investigators

  • Angelos P. Kassianos, PhD · Cyprus University of Technology

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-31
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • Cyprus

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05588973 on ClinicalTrials.gov